
Guest post by Ivy Scherbarth. Ivy is a Colorado/Wyoming FACES Coordinator for PPMD. Follow Ivy at her blog, Living Duchenne.
…
Continue
PPMD President Pat Furlong and Vice President of Research Sharon Hesterlee are attending MDA’s Scientific Conference this week in Washington, D.C. Most of what was presented are results that were previously announced. However, there were some interesting presentations, as well as, results worth repeating, that we wanted to share. Sharon and Pat will continue to blog from the conference:
From Pat Furlong
Interview with Thomas Voit
While the content…
ContinueAdded by PPMD on April 24, 2013 at 10:00am — 6 Comments

Below is the latest update PPMD has received from Dr. Rohit Batta, Global Medical Affairs and Patient Relations Leader in GSK's Rare Disease Unit :
ContinueThe purpose of this communication is provide an update to you, as you have requested, on GSK’s plans for providing the option of continued access to drisapersen for boys completing the US Ph IIb 48 week study (DMD114876)…
Added by PPMD on April 24, 2013 at 9:30am — No Comments

Added by Pat Furlong on April 22, 2013 at 12:00pm — No Comments

Guest post by Gail D. McVicker, Grandmother of Jake (10) and Ryan (6) - Pennsylvania
Duchenne: An Intergenerational Issue
Five years ago, I did not know the world of Duchenne muscular dystrophy existed. Before my young grandsons were officially diagnosed in 2008, my daughter told me that some genetic…
ContinueAdded by PPMD on April 17, 2013 at 2:49pm — 2 Comments

As you know, each month we feature someone in the community with Duchenne, that has done something really special to raise awareness and help us in our fight. This month, we are featuring 17-year-old Matt Scheivert, who doesn’t have Duchenne, but has already decided that he wants to continue to work in…
Added by Will Nolan on April 17, 2013 at 2:22pm — No Comments

This spring brings news of progress to the Duchenne community as Sarepta engages in talks with the Food and Drug Association (FDA) to determine if they agency will review an application for accelerated approval for the exon 51 skipping drug eteplirsen and releases its 74 month data…
ContinueAdded by Sharon Hesterlee on April 9, 2013 at 9:00pm — 5 Comments

Guest post by Ivy Scherbarth. Ivy is a Colorado/Wyoming FACES Coordinator for PPMD. Follow Ivy at her blog, Living Duchenne.
One interesting thing about silence is listening to…
ContinueAdded by PPMD on April 4, 2013 at 11:30pm — No Comments

A Call to Action for all NH Constituents!
Seacoast, New Hampshire- 8th grader Rebecca Gowing wanted to make a difference in her community. After learning that her sister’s classmate and friend, Lucas Currier, had Duchenne Muscular Dystrophy she took action to help raise funds and spread awareness, creating Art for A Cure…
ContinueAdded by Ryan Fischer on April 2, 2013 at 9:00pm — No Comments

Hello Duchenne community!
Summer is just around the corner and with that comes sunshine, fireflies and PPMD’s Annual Connect Conference.
We are excited to be back in Baltimore, MD at the beautiful Marriott Waterfront this year and really excited about this year’s program.
In 2013…
ContinueAdded by Kimberly Galberaith on April 2, 2013 at 11:30am — No Comments

On March 26, PPMD President Pat Furlong, along with other members of the Duchenne community (internationally, including those like Pat that traveled from the U.S.) met with the UK's Shadow Minister of Health, Andrew Burnham in a meeting at Parliament.
The Video
Setting the Stage
The meeting opened with a video, that of a 4-year-old boy, Jack, diagnosed in…
ContinueAdded by Pat Furlong on March 27, 2013 at 4:35pm — No Comments

Parent Project Muscular Dystrophy (PPMD) has awarded University of Minnesota researcher Dr. Rita Perlingeiro a grant for $220,000 to develop a therapeutic approach for Duchenne using a new type of "adult-derived" stem cell called "induced pluripotent stem cells" or "iPSCs." iPSCs can be created from non-controversial sources like skin, have the ability to multiply indefinitely, and can be coaxed to become many different kinds of tissue types.
Previously, Dr.…

Summit's Press Release:
ContinueSummit today outlines its future plans for the continued development of utrophin modulators for the treatment of DMD. Utrophin modulation is a disease modifying approach that has the potential to treat all genetic forms of DMD. Summit’s…
Added by PPMD on March 21, 2013 at 9:55am — No Comments

As we remind you to register for DuchenneConnect or…
Added by Will Nolan on March 15, 2013 at 11:00am — No Comments

Help Bring Run for Our Sons to your own backyard.
I hear it all the time, “I want to do a fundraiser but not sure what to do or where to start” – I ask “have you thought of doing a 5K or fun run in your community?” – The rest is Run for Our Sons history!
5Ks and fun runs are fast becoming one of PPMD’s…
ContinueAdded by Ryan Fischer on March 14, 2013 at 1:30pm — No Comments

We were thrilled that 119 parents/guardians were willing and able to complete the entire treatment preferences survey. We are analyzing the data. We are doing the first part of the data analysis in-house, and the second part with our health economist collaborator. Our plan is to present this information to the FDA, to industry and clinical…
ContinueAdded by Holly Peay on March 13, 2013 at 10:30am — No Comments

When Chris and Patrick died, there was no Internet, no way to connect. The days just after they died, life was busy but at the same time heartbreaking – there was so little time to think about anything. After all was over, silence settled in. We were left with the burden of living without them, of going on and trying to make some sense of it.
No one called, not…
ContinueAdded by Pat Furlong on March 12, 2013 at 4:32pm — 3 Comments

Added by Ryan Fischer on March 7, 2013 at 4:21pm — No Comments

Guest post by Ivy Scherbarth. Ivy is a Colorado/Wyoming FACES Coordinator for PPMD. Follow Ivy at her blog, Living Duchenne.…

PTC Therapeutics, Inc. (PTC) today announced the successful completion of a $60 million financing led by Brookside Capital Partners Fund, L.P.
Continue"This substantial financing enables PTC to continue to pursue the regulatory approval and delivery of ataluren to patients," stated Michael Schmertzler, Chairman of the Board. "PTC's Board of Directors welcomes the breadth of support and expertise of our new investors."…
Added by PPMD on March 7, 2013 at 2:00pm — No Comments
2013
2012
2011
2010
2009
2008
2007
Need help using this community site? Visit Ning's Help Page.
© 2013 Created by PPMD.